Renalytix PLC
LSE:RENX

Watchlist Manager
Renalytix PLC Logo
Renalytix PLC
LSE:RENX
Watchlist
Price: 10.75 GBX 7.93% Market Closed
Market Cap: 35.6m GBX
Have any thoughts about
Renalytix PLC?
Write Note

Renalytix PLC
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Renalytix PLC
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Renalytix PLC
LSE:RENX
Cash from Financing Activities
$15.1m
CAGR 3-Years
-3%
CAGR 5-Years
157%
CAGR 10-Years
N/A
Craneware PLC
LSE:CRW
Cash from Financing Activities
-$70m
CAGR 3-Years
N/A
CAGR 5-Years
-53%
CAGR 10-Years
-29%
Cambridge Cognition Holdings PLC
LSE:COG
Cash from Financing Activities
ÂŁ4.6m
CAGR 3-Years
N/A
CAGR 5-Years
15%
CAGR 10-Years
N/A
Intelligent Ultrasound Group PLC
LSE:IUG
Cash from Financing Activities
-ÂŁ236k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
EMIS Group PLC
LSE:EMIS
Cash from Financing Activities
-ÂŁ18.8m
CAGR 3-Years
4%
CAGR 5-Years
-3%
CAGR 10-Years
-6%
Doctor Care Anywhere Group PLC
ASX:DOC
Cash from Financing Activities
ÂŁ9.3m
CAGR 3-Years
-42%
CAGR 5-Years
28%
CAGR 10-Years
N/A
No Stocks Found

Renalytix PLC
Glance View

Market Cap
35.6m GBX
Industry
Health Care

Renalytix Plc manufactures medical devices and equipment. The company is headquartered in Penarth, South Glamorgan. The company went IPO on 2018-11-06. The firm is focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care. The firm's diagnostic platform, KidneyIntelX, is designed to scale across kidney disease conditions beyond diabetic kidney disease. The firm is evaluating a range of new indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and coronavirus disease (COVID)-related kidney disease. KidneyIntelX platform facilitates the identification and promotes the effective management of patients at risk of early-stage diabetic kidney disease (DKD), progression by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record (HER) using a proprietary algorithm to generate a unique patient risk score.

RENX Intrinsic Value
14.29 GBX
Undervaluation 25%
Intrinsic Value
Price

See Also

What is Renalytix PLC's Cash from Financing Activities?
Cash from Financing Activities
15.1m USD

Based on the financial report for Jun 30, 2023, Renalytix PLC's Cash from Financing Activities amounts to 15.1m USD.

What is Renalytix PLC's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
157%

Over the last year, the Cash from Financing Activities growth was -41%. The average annual Cash from Financing Activities growth rates for Renalytix PLC have been -3% over the past three years , 157% over the past five years .

Back to Top